Skip to main
ALT

Altimmune (ALT) Stock Forecast & Price Target

Altimmune (ALT) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Altimmune is a late clinical-stage biopharmaceutical company focused on developing therapies for serious liver diseases. The company's key drug candidate pemvidutide has a balanced dual-action mechanism targeting glucagon and GLP-1 receptors for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). Altimmune's PERFORMA protocol, a multinational Phase 3 trial for MASH, has been submitted to the FDA and is aligned with EMA feedback, with a targeted initiation in the second half of 2026 and a 52-week readout in 2029, which could provide a positive data point for pemvidutide. The company also has plans to pursue additional indications for pemvidutide that leverage its unique clinical profile. Altimmune has a strong financial position with cash, equivalents, and short-term investments of $332 million as of March 2021 and a pro forma level of $535 million after successful stock offerings, providing a runway through the PERFORMA trial.

Bears say

Altimmune is a late clinical-stage biopharmaceutical company, with its leading candidate pemvidutide targeting multiple indications in the liver disease space. While the candidate has shown promise in early trials, the company faces strong competition in the market and limited financial resources for its development. Additionally, the recent dilution of shares following a financing round has lowered the potential for future returns and reduced our price target to $11.

Altimmune (ALT) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Altimmune (ALT) Forecast

Analysts have given Altimmune (ALT) a Buy based on their latest research and market trends.

According to 4 analysts, Altimmune (ALT) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Altimmune (ALT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.